A new industry report highlights how peptide‑based therapies are beginning to reshape the treatment landscape for Alcohol Use Disorder (AUD). Covering more than 25 companies and investigational drugs, the analysis points to novel CNS pathways, genetically targeted therapies, and long‑acting formulations as the next frontier in addiction medicine.
Peptide Science in Addiction Treatment
Among the emerging candidates is Sunobinop from Imbrium Therapeutics, an oral compound designed to activate the nociceptin/orphanin FQ peptide receptor. This receptor is expressed across the central and peripheral nervous systems and plays a role in reward, stress, and behavioral regulation — all critical processes in addiction. By targeting this peptide receptor, Sunobinop aims to reduce alcohol craving and reinforce abstinence, and is currently in Phase II clinical development.
The report also categorizes pipeline drugs by molecule type, explicitly listing peptides, monoclonal antibodies, recombinant fusion proteins, and gene therapies alongside small molecules. This underscores how peptide biology is becoming a recognized pillar in AUD research.
Beyond Peptides: Complementary Strategies
Other highlighted candidates include AD04 (Adial Pharmaceuticals), a genetically targeted therapy linked to serotonergic and dopaminergic pathways, and BICX104 (BioCorRx Pharmaceuticals), a long‑acting naltrexone pellet designed to improve adherence. Together, these approaches reflect a broader push toward precision medicine, sustained delivery, and receptor‑specific modulation.
The Bigger Picture
Alcohol Use Disorder remains a heterogeneous condition influenced by genetic, neurobiological, and environmental factors. With approximately half of the risk believed to be heritable, peptide‑based receptor targeting offers a promising route to address the biological underpinnings of addiction.
For the peptide industry, the inclusion of therapies like Sunobinop signals a growing recognition that peptide receptor biology is not limited to oncology or metabolic disease — it is now entering the addiction space, where unmet need is vast and innovation has lagged.
OTHER NEWS: Peptide innovation is also reshaping pain care. See our coverage of Cebranopadol’s dual NOP/MOP mechanism, which shows how peptide pathways can reduce abuse potential while delivering effective analgesia.